This case suggests that precision medicine guided by biomarkers such as PD-L1, TMB, and MRD, combined with a multidisciplinary comprehensive strategy, may bring the possibility of radical treatment for patients with advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.